AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31083846 — intervention group
Group type: COMPARATOR
Intervention: Lecture on spiritual care (one session)
Number of subjects: 63
Study 29205601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment
Number of subjects: 336
Study 26407273 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (QIV)
Number of subjects: 314
Study 26407273 — intervention group
Group type: COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV)
Number of subjects: 314
Study 24687003 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental training
Number of subjects: 4
Study 24687003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosody training
Number of subjects: 4
Study 24687003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of segmental and prosody training
Number of subjects: 4
Study 24687003 — intervention group
Group type: COMPARATOR
Intervention: Baseline/withdrawal (A)
Number of subjects: 4
Study 22426247 — intervention group
Group type: COMPARATOR
Intervention: Adaptive design with dose escalation and cohort expansion
Number of subjects: 0
Study 22426247 — intervention group
Group type: COMPARATOR
Intervention: Adaptive design
Number of subjects: 0
Study 20716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable meniscal screws
Number of subjects: 42
Study 20716684 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable meniscus arrows
Number of subjects: 42
Study 20716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (screws and arrows)
Number of subjects: 42
Study 18042651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (5 pmol x kg(‐1) x min(‐1))
Number of subjects: 8
Study 15610655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern treatment strategies including chemotherapy and radiotherapy
Number of subjects: 0
Study 15610655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of chemotherapy doses or cycles
Number of subjects: 0
Study 15610655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-radiation doses and smaller radiation field sizes
Number of subjects: 0
Study 15610655 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense drug combinations for high-risk patients
Number of subjects: 0
Study 11844575 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 15
Study 11844575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10782751 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 (flavonoids diosmin 90% and hesperidin 10%)
Number of subjects: 28
Study 10782751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7735583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone exposure
Number of subjects: 11
Study 7735583 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 2044968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 20
Study 2044968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% MK-417
Number of subjects: 20
Study 2044968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2044968 — intervention group
Group type: EXPERIMENTAL
Intervention: CAI treatments (MK-927 and MK-417)
Number of subjects: 20
Study 2044968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK-417
Number of subjects: 20
Study 2044968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 20
Study 7080892 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing delay training
Number of subjects: 0
Study 7080892 — intervention group
Group type: COMPARATOR
Intervention: Rapid smoking
Number of subjects: 0
Study 30754074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 49
Study 30754074 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 49
Study 29756974 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises + lacto-vegetarian diet
Number of subjects: 21
Study 29756974 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lacto-vegetarian diet
Number of subjects: 21
Study 29756974 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 26749217 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 3 mg with naltrexone (50 mg initiated 12 hours before and given every 12 hours for 4 doses)
Number of subjects: 58
Study 26749217 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone alone (with placebo films)
Number of subjects: 58
Study 26749217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo films and placebo naltrexone)
Number of subjects: 58
Study 26749217 — intervention group
Group type: COMPARATOR
Intervention: Open-label moxifloxacin 400 mg with placebo naltrexone
Number of subjects: 58
Study 24199667 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 42
Study 24199667 — intervention group
Group type: COMPARATOR
Intervention: sweet-tasting placebo drink
Number of subjects: 42
Study 23143828 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric assessment and feedback systems
Number of subjects: 400
Study 23143828 — intervention group
Group type: COMPARATOR
Intervention: Peer review system based on qualitative individual case reports
Number of subjects: 400
Study 20813792 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (exact dosage not specified)
Number of subjects: 818
Study 20813792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 17999737 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride (SnF(2))
Number of subjects: 32
Study 17999737 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium fluoride (NaF)
Number of subjects: 32
Study 15890561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX) 100 mg orally once daily
Number of subjects: 178
Study 15890561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX) 300 mg orally once daily
Number of subjects: 178
Study 15890561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 178
Study 12190714 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider support for self-management of bipolar disorder
Number of subjects: 420
Study 9831969 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg loading dose of gentamicin or tobramycin (study group, n=4)
Number of subjects: 11
Study 9831969 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing regimen of 2 mg/kg loading dose followed by maintenance dose (control group, n=7)
Number of subjects: 11
Study 8092111 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin plus Amikacin (arm A)
Number of subjects: 70
Study 8092111 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (arm B)
Number of subjects: 70
Study 8092111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 2530716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccination
Number of subjects: 0
Study 2530716 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular hepatitis B vaccination
Number of subjects: 0
Study 31348243 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetostimulation
Number of subjects: 30
Study 31348243 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoledtherapy
Number of subjects: 30
Study 28504307 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention (FSI‐HIV)
Number of subjects: 170
Study 28504307 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 170
Study 26363186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching by speech-language pathologists (4 in-service workshops plus 5 individualized coaching sessions)
Number of subjects: 32
Study 26363186 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 workshops only)
Number of subjects: 32
Study 26363186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching by speech-language pathologists
Number of subjects: 32
Study 23368827 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 14
Study 23368827 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (D + E)
Number of subjects: 14
Study 21993710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg once daily)
Number of subjects: 577
Study 21993710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 21993710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 577
Study 19624387 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine, 300-600 mg/day
Number of subjects: 32
Study 19624387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16687036 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMizer Extra band
Number of subjects: 60
Study 16687036 — intervention group
Group type: COMPARATOR
Intervention: Classical bands
Number of subjects: 60
Study 14741082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 g
Number of subjects: 120
Study 14741082 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin (AP) high-dose according to Hammersmith
Number of subjects: 120
Study 14741082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 120
Study 14741082 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin (AP)
Number of subjects: 120
Study 11281506 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 71
Study 11281506 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 71
Study 9221454 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 1374
Study 9221454 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 1374
Study 8038000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120
Study 8038000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3326574 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) mask
Number of subjects: 10
Study 3326574 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 10
Study 3326574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary card evaluation during PEP mask therapy
Number of subjects: 10
Study 3326574 — intervention group
Group type: COMPARATOR
Intervention: Diary card evaluation during postural drainage
Number of subjects: 10
Study 29453419 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent intervention using a lower literacy, less dense form
Number of subjects: 188
Study 29453419 — intervention group
Group type: COMPARATOR
Intervention: Standard consent encounter
Number of subjects: 188
Study 27507856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 6756
Study 27507856 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Open Control
Number of subjects: 6756
Study 24627301 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 33
Study 24627301 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 33
Study 24627301 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 1000 mg
Number of subjects: 33
Study 24627301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 33
Study 24627301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 40 mg
Number of subjects: 33
Study 24627301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 22162575 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin (GC)
Number of subjects: 238
Study 22162575 — intervention group
Group type: COMPARATOR
Intervention: methotrexate/carboplatin/vinblastine (M-CAVI)
Number of subjects: 238
Study 21280424 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice
Number of subjects: 100
Study 21280424 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (Crest Cavity Protection)
Number of subjects: 100
Study 18798500 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 1.6 mg hypodermic injection, administered for 10 times
Number of subjects: 80
Study 18798500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 18798500 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Number of subjects: 80
Study 16395874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangla translation of the Youth Self-Report (YSR) questionnaire
Number of subjects: 365
Study 16395874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangla version of the YSR
Number of subjects: 365
Study 12775884 — intervention group
Group type: EXPERIMENTAL
Intervention: Central retinal artery (CRA) Doppler flowmetry
Number of subjects: 103
Study 12775884 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (adjusted)
Number of subjects: 103
Study 12775884 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of small infarcts
Number of subjects: 103
Study 12775884 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade of periventricular hyperintensities
Number of subjects: 103
Study 10379630 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 195
Study 10379630 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 195
Study 8885956 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. dosing
Number of subjects: 25
Study 8885956 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. dosing
Number of subjects: 25
Study 8885956 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. and titration conditions
Number of subjects: 25
Study 8885956 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. and t.i.d. schedules
Number of subjects: 25
Study 2063702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie control, sodium restriction, potassium increases
Number of subjects: 841
Study 2063702 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of urine sodium, urine potassium, and weight
Number of subjects: 841
Study 2063702 — intervention group
Group type: EXPERIMENTAL
Intervention: Household composition and control over food selection/preparation
Number of subjects: 841
Study 2063702 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of complaints about diets
Number of subjects: 841
Study 2063702 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at treatment sessions
Number of subjects: 841
Study 6391932 — intervention group
Group type: EXPERIMENTAL
Intervention: diflunisal 1000 mg daily
Number of subjects: 47
Study 6391932 — intervention group
Group type: COMPARATOR
Intervention: naproxen 750 mg daily
Number of subjects: 47
Study 30486711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 132
Study 30486711 — intervention group
Group type: COMPARATOR
Intervention: Control group (guideline-directed therapy for HF)
Number of subjects: 132
Study 27171812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Nursing Path (CNP)
Number of subjects: 120
Study 27171812 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care (Control)
Number of subjects: 120
Study 26355171 — intervention group
Group type: EXPERIMENTAL
Intervention: BB group (anorganic bovine bone (Bio‐Oss) and collagen porcine membranes (Bio‐Gide))
Number of subjects: 50
Study 26355171 — intervention group
Group type: EXPERIMENTAL
Intervention: BB group
Number of subjects: 50
Study 26355171 — intervention group
Group type: COMPARATOR
Intervention: CJ group (synthetic resorbable bone graft substitute made of pure β‐tricalcium phosphate (Ceros TCP) and porcine pericardium collagen membranes (Jason))
Number of subjects: 50
Study 23453726 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training (24 sessions over 8 weeks, 20 minutes walking per session)
Number of subjects: 19
Study 23453726 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training
Number of subjects: 19
Study 23453726 — intervention group
Group type: COMPARATOR
Intervention: Non-disabled group (comparison group)
Number of subjects: 19
Study 21956960 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol (vitamin E)
Number of subjects: 100
Study 21956960 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐carotene
Number of subjects: 100
Study 21956960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both α‐tocopherol and β‐carotene
Number of subjects: 100
Study 21956960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18829623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk
Number of subjects: 23
Study 18829623 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy
Number of subjects: 23
Study 17196488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60
Study 17196488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60
Study 17196488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 30 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60
Study 17196488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 40 microg with bupivacaine 0.5% hyperbaric
Number of subjects: 60
Study 17196488 — intervention group
Group type: COMPARATOR
Intervention: Saline with bupivacaine 0.5% hyperbaric (control group)
Number of subjects: 60
Study 16305005 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush and dental water jet (Group 2)
Number of subjects: 105
Study 16305005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush and dental water jet (Group 3)
Number of subjects: 105
Study 16305005 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush and floss (Group 1)
Number of subjects: 105
Study 12077088 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg intravenously three times a week for two weeks)
Number of subjects: 299
Study 12077088 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg intravenously three times a week for four weeks)
Number of subjects: 299
Study 12077088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 12077088 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302
Number of subjects: 299
Study 10213349 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=12)
Number of subjects: 27
Study 10213349 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 27
Study 7593704 — intervention group
Group type: COMPARATOR
Intervention: Hibident (positive control)
Number of subjects: 6
Study 7593704 — intervention group
Group type: COMPARATOR
Intervention: Parodex
Number of subjects: 6
Study 7593704 — intervention group
Group type: COMPARATOR
Intervention: Prexidine
Number of subjects: 6
Study 7593704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alodont
Number of subjects: 6
Study 7593704 — intervention group
Group type: EXPERIMENTAL
Intervention: Eludril
Number of subjects: 6
Study 7593704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hextril
Number of subjects: 6
Study 7593704 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 6
Study 7593704 — intervention group
Group type: COMPARATOR
Intervention: Hibident, Parodex, Prexidine
Number of subjects: 6
Study 7593704 — intervention group
Group type: EXPERIMENTAL
Intervention: Eludril, Hextril
Number of subjects: 6
Study 2229840 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (2 gm)
Number of subjects: 10
Study 2229840 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 10
Study 656251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 20
Study 656251 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 20
Study 656251 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 30621460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-based pressure injury prevention program
Number of subjects: 25
Study 31397702 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular BPB
Number of subjects: 40
Study 31397702 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular BPB
Number of subjects: 40
Study 31397702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral hemidiaphragmatic paresis present
Number of subjects: 40
Study 28237428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct slow-release dexamethasone implant (Ozurdex; 0.7 mg)
Number of subjects: 140
Study 28237428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 140
Study 28237428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct slow-release dexamethasone implant (Ozurdex)
Number of subjects: 140
Study 25475363 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month social communication intervention including parent training
Number of subjects: 61
Study 25475363 — intervention group
Group type: COMPARATOR
Intervention: Observation of sessions
Number of subjects: 61
Study 25475363 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coaching and workshops
Number of subjects: 61
Study 25475363 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' implementation of strategies
Number of subjects: 61
Study 24045678 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 7.5 mg
Number of subjects: 1184
Study 24045678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study 21197524 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT with blue light source
Number of subjects: 18
Study 21197524 — intervention group
Group type: COMPARATOR
Intervention: MAL-PDT with red light source
Number of subjects: 18
Study 19414940 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg after each dialysis session for six months
Number of subjects: 16
Study 19414940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19414940 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone and Placebo
Number of subjects: 16
Study 17879663 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril yoga breathing
Number of subjects: 20